Wikipedia -WSS

Wikipedia

author：leisure time 2025-10-03 00:38:34 - browse：2513

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Anthos stroke drug appears safer than common blood thinner

WSS

Hospitals look to new technology to keep health care workers safe

Roivant's CEO is a star, but biotech's black hole persists

Childhood cancer progress stalls for Black, Hispanic kids: Report

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Wegovy, Zepbound and weight loss drugs that preserve muscle

STAT Readout Newsletter: Biotech news today

knowledge

Wikipedia

hotspot

Medical leaders decry Supreme Court decision on affirmative action

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Affirmative action in medical school literally saved lives

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Medicare details structure of new drug price negotiation program

Morphosys mixed study results for blood cancer drug

Medical leaders decry Supreme Court decision on affirmative action

Gain of function research would be limited under House proposal

Moonlake's readout produced a cash windfall. Risks remain

NYU radiologists take on the challenge of expensive MRI machines

focus

Congress must reauthorize a committee to support older Americans

Poor hospice wound care hurts patients and families

ADCs take center stage as promising cancer treatments

CZI to create biohub to build anti

Study on Amgen’s bispecific immunotherapy produces positive data

Is there really a nursing shortage in the U.S.?

hotspot

focus

entertainment

leisure time